Xiamen, China - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13), an innovative, commercial-stage, biopharmaceutical company, announced the signing of a strategic cooperation agreement in the companion diagnostic field. The agreement will enable the two sides to jointly promote the development of molecular diagnostics in Osimertinib/Savolitinib Combo treatment for NSCLC in the Chinese market.
“We are excited about the collaboration with HUTCHMED. Together the two parties will promote the development of precision treatment in the field of lung cancer and deliver more accurate diagnostics for the patients. Since being founded in 2008, AmoyDx has been focusing on molecular diagnostics for precision oncology. To bring patients more advanced solutions and treatment options, we continue to develop innovative products and work with global and national pharmaceutical companies. We believe that our cooperation will certainly deliver more good news to patients and bring more innovative technologies to the industry.” Li-Mou Zheng, Ph.D., Founder and Chief Executive Officer of AmoyDx, commented.
“We are committed to the discovery and global development & commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. We are thrilled to collaborate with AmoyDx, a pioneer and globally leading company in the field of molecular diagnostics for precision oncology. Companion diagnostic is vital to recommend on indications for savolitinib treatment in NSCLC patients with high MET expression.” Weiguo Su, Executive Director and Chief Scientific Officer of HUTCHMED, commented,
About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)
Amoy Diagnostics Co., Ltd. is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit www.amoydiagnostics.com
About HUTCHMED (Nasdaq/AIM:HCM; HKEX:13)
HUTCHMED is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com
About Savolitinib (Orpathys®)
Savolitinib is a receptor tyrosine kinase mesenchymal epithelial transition factor (MET) inhibitor being developed for the treatment of metastatic non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma (RCC), gastric cancer and colorectal cancer. Based on the results of a pivotal phase II trial in patients with NSCLC/pulmonary sarcomatoid carcinoma, savolitinib was recently granted approval in China (conditional on the results of a phase III trial) for the treatment of metastatic NSCLC with MET exon 14-skipping alterations in patients who have progressed after or who are unable to tolerate platinum-based chemotherapy.
About Osimertinib (Tagrisso™)
Osimertinib is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR. In November 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.